Business, energy, technology, markets and global industry news from Business News Today

PD-1 inhibitor

PharmaDeviceNews PD-1 inhibitor
Pharma & Biotech

How Bristol Myers Squibb’s Opdivo approvals in frontline and relapsed classical Hodgkin lymphoma reset treatment pathways

Nivolumab wins U.S. frontline and EU relapsed cHL approvals. Analyse what the dual verdict means for sequencing, safety, and reimbursement.

Read More
Pharma & Biotech

Junshi Biosciences pushes subcutaneous PD-1 therapy as China’s oncology system strains

NMPA reviews subcutaneous toripalimab across 12 cancers. Discover how the delivery shift could reshape China’s immunotherapy infrastructure.

Read More
Pharma & Biotech

Akeso’s cadonilimab outperforms PD-1 inhibitors in real-world gastric cancer study

Cadonilimab outperforms PD-1 inhibitors in PD-L1-low gastric cancer patients. Find out what this means for global immunotherapy standards.

Read More